Get the Stockscreener App
41.26
3.87%
-1.66
After Hours:
41.26
Ultragenyx Pharmaceutical Inc stock is traded at $41.26, with a volume of 694.53K.
It is down -3.87% in the last 24 hours and down -4.97% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
See More
Previous Close:
$42.92
Open:
$42.64
24h Volume:
694.53K
Relative Volume:
0.89
Market Cap:
$3.87B
Revenue:
$522.75M
Net Income/Loss:
$-558.99M
P/E Ratio:
-6.3771
EPS:
-6.47
Net Cash Flow:
$-439.53M
1W Performance:
-1.39%
1M Performance:
-4.97%
6M Performance:
-25.94%
1Y Performance:
-23.15%
1-Day Range:
$40.85
$43.22
1-Week Range:
$39.74
$43.54
52-Week Range:
$37.02
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
41.26 | 3.87B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Ultragenyx EVP Karah Parschauer sells $128,223 in stock - Investing.com India
(RARE) Technical Pivots with Risk Controls - Stock Traders Daily
Y Intercept Hong Kong Ltd Raises Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical's (RARE) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Ultragenyx reports 29% revenue jump in 2024, trims loss - The Santa Rosa Press Democrat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $93.50 Average Price Target from Analysts - MarketBeat
Ultragenyx Pharmaceutical, Inc. to Host Earnings Call - ACCESS Newswire
Cantor Fitzgerald maintains $118 target on Ultragenyx stock By Investing.com - Investing.com Canada
Ultragenyx's SWOT analysis: rare disease biotech stock faces pivotal year By Investing.com - Investing.com South Africa
Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com
Cantor Fitzgerald maintains $118 target on Ultragenyx stock - Investing.com India
Ultragenyx to Participate at Investor Conferences in March - GlobeNewswire
Can Ultragenyx's Triple Conference Schedule Signal Major Pipeline Updates? - StockTitan
Peregrine Capital Management LLC Buys 29,684 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright maintains Buy on Ultragenyx with $95 target By Investing.com - Investing.com Australia
Ultragenyx granted FDA priority review for gene therapy in rare brain disorder - MSN
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Ultragenyx Reports Strong Growth Amid Challenges - TipRanks
Ultragenyx Pharmaceutical Inc. SEC 10-K Report - TradingView
Inside Ultragenyx's Latest Executive Compensation Package: New Hires Receive Strategic RSU Grants - StockTitan
Canaccord Genuity Group Boosts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $136.00 - MarketBeat
H.C. Wainwright maintains Buy on Ultragenyx with $95 target - Investing.com India
Trend Tracker for (RARE) - Stock Traders Daily
Ultragenyx's SWOT analysis: rare disease biotech stock eyes pivotal year By Investing.com - Investing.com South Africa
Canaccord raises Ultragenyx target to $136, keeps Buy rating By Investing.com - Investing.com Australia
Ultragenyx stock gains on FDA priority review (RARE:NASDAQ) - Seeking Alpha
Canaccord raises Ultragenyx target to $136, keeps Buy rating - Investing.com India
Ultragenyx Announces FDA Acceptance and Priority Review of - GlobeNewswire
Ultragenyx's Revolutionary Gene Therapy for Fatal Childhood Disease Advances: FDA Fast-Tracks Review - StockTitan
Ultragenyx's SWOT analysis: rare disease biotech stock eyes pivotal year - Investing.com India
Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Call Transcript - Insider Monkey
Ultragenyx Pharmaceutical: Strong Growth Prospects and Pipeline Advancements Reinforce Buy Rating - TipRanks
Ultragenyx stock holds Buy rating, $140 target from Truist - MSN
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use - MSN
Goldman Sachs maintains buy on Ultragenyx, target at $78 - MSN
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y - MSN
HC Wainwright Reiterates "Buy" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE) - MarketBeat
Breaking Down Ultragenyx Pharmaceutical: 7 Analysts Share Their Views - Benzinga
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):